{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:34:35Z","timestamp":1747172075805,"version":"3.40.5"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.urolonc.2024.04.017","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T12:22:33Z","timestamp":1714393353000},"page":"290.e11-290.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and management of prostatic urethra recurrence in a cohort of 21 patients who received BCG induction for non-muscle invasive bladder cancer"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9674-3456","authenticated-orcid":false,"given":"Justin W.","family":"Ingram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainjade","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Laplaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew T.","family":"Lenis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7062-5001","authenticated-orcid":false,"given":"Christopher B.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2024.04.017_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.urolonc.2024.04.017_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3050","article-title":"Management, surveillance patterns, and costs associated with low-grade papillary stage ta non\u2013muscle-invasive bladder cancer among older adults, 2004-2013","volume":"5","author":"Bree","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2024.04.017_bib0003","unstructured":"Anderson CB, McKiernan JM. 80 - tumors of the urethra."},{"issue":"5","key":"10.1016\/j.urolonc.2024.04.017_bib0004","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0022-5347(01)62459-5","article-title":"Extravesical tumor relapse in patients with superficial bladder tumors","volume":"160","author":"Herr","year":"1998","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.04.017_bib0005","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with Bacillus Calmette-Gu\u00e9rin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2024.04.017_bib0006","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1007\/s00345-019-02673-2","article-title":"Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer","volume":"37","author":"Brant","year":"2019","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.04.017_bib0007","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2005.03.021","article-title":"Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy","volume":"48","author":"Huguet","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.04.017_bib0008","unstructured":"National comprehensive cancer network clinical practice guidelines in bladder cancer version 1. 2023-February 9, 2023."},{"issue":"4","key":"10.1016\/j.urolonc.2024.04.017_bib0009","first-page":"290","article-title":"Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy","volume":"22","author":"Bianco","year":"2004","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"4","key":"10.1016\/j.urolonc.2024.04.017_bib0010","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2024.04.017_bib0011","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1464-410X.2008.08210.x","article-title":"Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Gu\u00e9rin immunotherapy?","volume":"103","author":"Gofrit","year":"2009","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.urolonc.2024.04.017_bib0012","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1464-410X.2009.08525.x","article-title":"Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer","volume":"104","author":"Patel","year":"2009","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.urolonc.2024.04.017_bib0013","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-5347(17)41031-7","article-title":"Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra","volume":"141","author":"Bretton","year":"1989","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.04.017_bib0014","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.eururo.2003.12.014","article-title":"Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder","volume":"45","author":"Canda","year":"2004","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.04.017_bib0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0090-4295(89)90314-2","article-title":"Conservative treatment of superficial transitional cell carcinoma of prostatic urethra with intravesical BCG","volume":"34","author":"Orihuela","year":"1989","journal-title":"Urology"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924004368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924004368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T19:47:40Z","timestamp":1718826460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924004368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1078143924004368"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.04.017","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and management of prostatic urethra recurrence in a cohort of 21 patients who received BCG induction for non-muscle invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}